Reasons for receiving alloHCT after targeted therapies
| . | n (%) . |
|---|---|
| del(17p)* | 22 (76) |
| No. of prior therapies ≥3 | 22 (73) |
| Complex karyotype (≥5 abnormalities)* | 12 (46) |
| IGHV unmutated* | 15 (79) |
| Refractory to or relapsed after FCR prior to targeted therapy | 4 (13) |
| Poor response to conventional chemotherapy | 2 (7) |
| Poor response to targeted therapy | 3 (10) |
| Richter transformation | 3 (10) |
| . | n (%) . |
|---|---|
| del(17p)* | 22 (76) |
| No. of prior therapies ≥3 | 22 (73) |
| Complex karyotype (≥5 abnormalities)* | 12 (46) |
| IGHV unmutated* | 15 (79) |
| Refractory to or relapsed after FCR prior to targeted therapy | 4 (13) |
| Poor response to conventional chemotherapy | 2 (7) |
| Poor response to targeted therapy | 3 (10) |
| Richter transformation | 3 (10) |
FCR, fludarabine, cyclophosphamide, and rituximab.
Missing data are excluded from the denominator in calculation of percentage. The denominator is 29, 26, and 19 for del(17p), complex karyotype, and IGHV unmutated, respectively.